Clinical Trials Logo

Immune System Diseases clinical trials

View clinical trials related to Immune System Diseases.

Filter by:

NCT ID: NCT03351543 Completed - Clinical trials for Immune System Disorders

Effect of Microbial Exposure on Health, Particularly Immune System

ADELEWP1t4
Start date: March 2016
Phase: Phase 1
Study type: Interventional

The effect of microbial exposure on healthy human subjects will be investigated. Changes in cytokine and IgE and vaccine response will be measured. The hypothesis is that microbial exposure increases the measured responses.

NCT ID: NCT03345004 Completed - Diabetes Mellitus Clinical Trials

Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes

Start date: December 20, 2017
Phase: Phase 2
Study type: Interventional

The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous insulin secretion as measured by C-peptide.

NCT ID: NCT03337165 Completed - Clinical trials for Arthritis, Rheumatoid

Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis

TolDCfoRA
Start date: December 2016
Phase: Phase 1
Study type: Interventional

Tolerogenic dendritic cell (tDC)-based clinical trials for the treatment of autoimmune diseases are now a reality. Clinical trials are currently exploring the effectiveness of tDC to treat of type 1 diabetes mellitus, rheumatoid arthritis, multiple sclerosis and Crohn's disease. The general objective of this study is to evaluate the safety and tolerability of a single intra-articular injection (into the knee joint) of autologous monocyte-derived dendritic cells generated in the presence of interferon-alpha (IFN-α)/granulocyte-macrophage colony-stimulating factor (GM-CSF) and tolerized with Dexamethasone in rheumatoid arthritis (RA) patients.

NCT ID: NCT03332225 Completed - Sepsis Clinical Trials

A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis

PROVIDE
Start date: December 15, 2017
Phase: Phase 2
Study type: Interventional

The aim of the study is to conduct one RCT of personalized immunotherapy in sepsis targeting patients who lie either on the predominantly hyper-inflammatory arm or on the predominantly hypo-inflammatory arm of the spectrum of the host response. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be randomly allocated to placebo or immunotherapy treatment according to their needs.

NCT ID: NCT03280797 Completed - Clinical trials for Rheumatoid Arthritis

Feasibility of a Cytokine Expression Profile in Immune Cells as an Orientation Tool in Therapeutic Decisions for Auto-inflammatory and Auto-immune Diseases

IL-MAI
Start date: November 24, 2017
Phase: N/A
Study type: Interventional

This study will assess the feasibility of using cytokine expression profiles in blood samples as a method for evaluating rheumatoid polyarthritis

NCT ID: NCT03225950 Completed - Clinical trials for Rheumatoid Arthritis

Interaction Between Immune Cells and Bacteria Associated With Periodontitis

Start date: February 1, 2017
Phase:
Study type: Observational

This study evaluates the interaction between host immune cells and bacteria associated with periodontitis. It comprises biological material from donors with and without periodontal disease. Specifically, we collect a spit and blood sample to conduct in vitro stimulations and measurements of selected parameters related to periodontitis to clarify obscure areas in the immunologic pathogenesis of this disease.

NCT ID: NCT03199638 Completed - Diabetes Mellitus Clinical Trials

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

This project will assess the feasibility and efficacy of the use of exercise and dietary supplementation with a non essential amino acid - glutamine - a component of most protein supplements, on the regulation of plasma glucose homeostasis in a clinical setting of children with type 1 diabetes (T1D). The study specifically targets patients in puberty as this period is associated with a physiological decline in insulin sensitivity, the latter often associated with poor control. Although physical exercise has long been known to exert beneficial effects on metabolism, lack of time is the most common reason perceived as preventing the performance of exercise in both healthy and diabetic subjects. In earlier studies, the investigators showed that oral supplementation with glutamine, a non essential amino acid given prior to exercise decreases overnight post-exercise blood glucose in adolescents with T1D. Hence, the objective of the current study is to investigate if a novel way of exercising, such as performing 6 short bouts of just 1 min each of intense exercise ('exercise snacks') 30 min before meals, with or without glutamine, improves glycemic control in adolescents with T1D. Designing innovative ways to improve diabetes control in adolescents is highly desirable. The specific aim of the project is to determine whether the sustained use of the proposed exercise snacks with or without glutamine results in diminished glycemic variability and/or improved glucose control

NCT ID: NCT03161288 Completed - Clinical trials for Immune System Diseases

A Study of KY1005 in Healthy Volunteers

Start date: May 29, 2017
Phase: Phase 1
Study type: Interventional

This is a single and multiple ascending dose, placebo-controlled, double-blind, Phase 1 study to evaluate the safety and tolerability of KY1005 in healthy volunteers.

NCT ID: NCT03054428 Completed - Dermatitis, Atopic Clinical Trials

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Start date: March 21, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to demonstrate the efficacy of dupilumab as a monotherapy in participants ≥12 years to <18 years of age with moderate-to-severe atopic dermatitis (AD). The secondary objective of the study was to assess the safety of dupilumab as a monotherapy in participants ≥12 years to <18 years of age with moderate-to-severe AD.

NCT ID: NCT02981992 Completed - Immune Dysfunction Clinical Trials

T Regulatory Cells in Hemodialysis Patients: Observational Study

Start date: February 2011
Phase: N/A
Study type: Observational

In this observational study, the investigators evaluated the Treg number and function in a population of patients undergoing hemodialysis (HD). In particular, the investigators considered the relationship of Treg cell status with the different HD modalities and clinical parameters.